Cardiac contractility modulation (CCM™) is a device based therapy which EU Studies have shown to be an effective treatment option for patients with Chronic Heart Failure (CHF). CCM™ therapy will now be made available to patients in the Nordic region by consultation with their treating doctors.
An estimated 250 000 individuals in Sweden suffer from CHF, a disease where the heart loses its ability to properly pump blood to all the organs. This results in severe symptoms that have a significant negative effect on quality of life and mortality. Approximately 70% of these patients (CHF patients with narrow QRS complex) do not benefit from currently available device therapy and to date the only available option for these patients has been standard pharmacological treatment.
Impulse Dynamics, developer of the CCM™ therapy and the Optimizer® devices has primarily focused on its home market Germany while collecting strong scientific evidence of the therapy, but is now expanding and is in the process of establishing a Nordic organization that will support the implanting hospitals and patients in the Nordic countries.
“With the strong clinical evidence we have collected for CCM™ and Optimizer®, and with the support from the scientific community we are excited to offer the therapy in growing number of countries.” said Mateusz Zelewski, VP International Sales at Impulse Dynamics. “Impulse Dynamics is committed to provide the best professional support to every new customer.”
The Optimizer® device is already on its fifth generation and is CE marked and approved for use in EU. More than 3500 patients have received CCM™ treatment with the Optimizer® system and as of 2016 CCM™ is also mentioned in the ESC guidelines as treatment option for CHF patients with narrow QRS.
Mateusz Zelewski, Impulse Dynamics – VP International Sales
Phone: +48 602 225580
Niklas Magnusson, Impulse Dynamics – Regional Sales Manager Nordics
Phone: +46 70 5100215
For more information on CCM™, Optimizer® and Impulse Dynamics see the company website:
For scientific material on CCM™ see the company website (or PubMed):
For more information on Heart failure: http://www.hjart-lung.se/hjarta/diagnos-hjarta/hjartsvikt/
The Optimizer® Smart device, which delivers CCM™ therapy, has been successfully launched in Europe and is available in a growing number of cardiology centers. Over 3000 patients worldwide have already received CCM™ through the Optimizer® III or IVs device, the only device therapy available for patients with a narrow QRS complex. Impulse Dynamics has completed extensive clinical studies, including several randomized controlled trials, published in articles in over 60 leading medical journals. The Optimizer® Smart is not currently approved for use in the United States; the Optimizer® IVs, an earlier version of the device, is approved in the United States for investigational use only.
Impulse Dynamics N.V., a member of the Hobart Group of companies, is focused on the development of electrical therapies for the treatment of chronic heart failure. As a global leader in cardiac medical innovation, Impulse Dynamics has operations in the United States, Europe, Asia and Australia. For more information, please visit www.impulse-dynamics.com.
CCM™ and Optimizer® are trademarks of Impulse Dynamics N.V.
Director, Investor Relations and
New Business Ventures, Hobart Group
For EU release only, device for investigational use only in US